Top Market Shifts Transforming the Biologics Testing Market Landscape: Key Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Biologics Testing Market Through 2025?
The market size for biologics testing has seen substantial expansion in the past few years. The market, which stood at $5.92 billion in 2024, is projected to increase to $6.85 billion in 2025, indicating a compound annual growth rate (CAGR) of 15.7%. The factors driving this notable growth during the historic period encompass the development of biologics, strict regulatory guidelines, quality control in bioprocessing, higher investments in biopharmaceuticals, and an expansion in biomanufacturing capacity.

What's the Projected Size of the Global Biologics Testing Market by 2029?
Over the coming years, the biologics testing market is projected to experience accelerated growth, expanding to "$12.91 billion by 2029 with an impressive CAGR of 17.2%. This growth during the forecast period is driven by factors such as the introduction of advanced therapies, the rising need for contract testing services, an expanding biologics pipeline, the globalization of biopharmaceutical manufacturing, and an increasing demand for speedy testing solutions. Notable trends for the forecast period incorporate advanced analytical technologies, cell-based assays, next-generation sequencing (NGS), quality by design (QBD) principles, along with the integration of artificial intelligence (AI) and improved methods for product release.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Top Growth Drivers in the Biologics Testing Industry: What's Accelerating the Market?
The swift expansion of the pharmaceutical and biotech sectors is set to drive the burgeoning biologics testing market. The chief concern of the pharmaceutical industry is the development and production of medications for various health issues and diseases. In contrast, the biotechnology sector is geared towards the utilisation of technology in biology and healthcare. Biologics testing comprises tests to detect and calculate impurities, measure stability, and assess the immune response to the drug. The expansion of the pharmaceutical and biotech sectors has also resulted in progress in biologics testing technology, like the advent of novel analytical instruments and methods, enabling more precise and effective testing and lowering the time and cost of launching new biologics into the market. For example, in July 2024, as per Eurostat, a governing institution based in Belgium, there was a rise in the pharmaceutical production in the EU from €36 billion ($39.4 billion) in 2021 to €44 billion ($46.7 billion) in 2023, indicating substantial growth in this sphere. Hence, the swiftly expanding pharmaceutical and biotech sectors are fuelling the growth of the biologics testing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10276&type=smp

What Trends Will Shape the Biologics Testing Market Through 2029 and Beyond?
Product innovation is a major trend gaining traction in the biologics testing market. Businesses in this sector are embracing novel products to maintain their market presence. For instance, in December 2022, Charles River Laboratories International, Inc., a non-clinical contract research organization based in the US, introduced the Endosafe Nexus 200, a latest addition to its comprehensive line of endotoxin testing tools. The Nexus 200, a data integrity-compliant, fully robotic device, is the culmination of Charles River's progress. It employs Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology and is capable of performing straightforward or intricate serial dilutions for water, in-process, and final product analysis. Run on the Endosafe EndoScan-V version 6.1, it allows for data export to a Laboratory Information Management System (LIMS) interface, offering improved traceability, security, and data management via an integrated display screen.

What Are the Main Segments in the Biologics Testing Market?
The biologics testing market covered in this report is segmented -

1) By Product: Reagents And Kits, Instruments, Other Products
2) By Test Type: Endotoxin Test, Sterility Test, Mycoplasma Tests, Bioburden Tests, Residual Host-Cell Proteins And DNA Detection Tests, Virus Safety Test, Other Test Types
3) By Application: Vaccine Development And Manufacturing, Monoclonal Antibodies Development And Manufacturing, Cellular And Gene Therapy Products Development And Manufacturing, Blood And Blood Products Development And Manufacturing, Other Applications

Subsegments:
1) By Reagents And Kits: ELISA Kits, PCR Kits, Cell Culture Reagents, Other Assay Kits
2) By Instruments: Spectrophotometers, Chromatography Systems, Microplate Readers, Other Analytical Instruments
3) By Other Products: Software, Consumables, Reference Standards

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10276&type=smp

Which Top Companies are Driving Growth in the Biologics Testing Market?
Major companies operating in the biologics testing market include Charles River Laboratories Inc., Thermo Fisher Scientific Inc., Merck KGaA, SGS Société Générale de Surveillance SA, WuXi AppTec Co. Ltd., Sartorius AG, Cytovance Biologics Inc., Pace Analytical Services Inc., Avance Biosciences Inc., Celgene Corporation, Biomerieux SA, Lonza Group Ltd., Genscript Biotech Corp., Bio-Rad Laboratories Inc., Accugen Laboratories Inc., Gibraltar Laboratories Inc., Jordi Labs, Gilead Sciences Inc., Bioquell Limited, Southern Research, Promega Corporation, Lancaster Laboratories Inc., Toxikon Corporation, Eurofins BioPharma Product Testing, Johnson & Johnson Inc., QIAGEN N.V., GlaxoSmithKline plc, Danaher Corporation, Agilent Technologies Inc., PerkinElmer Inc., Abbott Laboratories, Beckman Coulter Inc., Becton dic*kinson and Company, Roche Holding AG, Novartis AG, Eli Lilly and Company, Pfizer Inc.

Which Regions Will Dominate the Biologics Testing Market Through 2029?
North America was the largest region in the biologics testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global biologics testing market duirng the forecast period. The regions covered in the biologics testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10276

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.